证券代码：600436 证券简称：片仔癀 公告编号：2024-028 漳州片仔癀药业股份有限公司 2023 年年度 权益分派实施公告 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次利润分配方案经公司 2024 年 5 月 20 日的 2023 年年度股东大 会审议通过。 重要内容提示： 每股分配比例 A 股每股现金红利 2.32 元 相关日期 | 股份类别 | 股权登记日 | 最后交 | 除权（息）日 | 现金红利 | | --- | --- | --- | --- | --- | | | | 易日 | | 发放日 | | Ａ股 | 2024/6/6 | － | 2024/6/7 | 2024/6/7 | 1 二、 分配方案 本次利润分配以方案实施前的公司总股本 603,317,210 股为基数， 每 股 派 发 现 金 红 利 2.32 元 （ 含 税 ）， 共 计 派 发 现 金 红 利 1,399,695,927.20 元。 三、 相关日期 | 股份类别 ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 15% and a net profit growth of 13% for the year, indicating strong performance despite economic uncertainties [9] - The gross margin for the company is reported to be around 79%, which is considered exceptional in the traditional Chinese medicine industry [9] Business Line Data and Key Metrics Changes - The company has seen a significant increase in the sales of liver disease medications, rising from 338 million boxes at the end of 2022 to 453 million boxes at the end of 2023 [6] - The inventory of liver disease medications decreased from 85 million boxes to 33 million boxes, indicating a potential supply issue if production does not keep pace with demand [6] Market Data and Key Metrics Changes - The company has established over 400 "Famous Doctor Clinics" and plans to increase this number significantly in the next 3-5 years, with a target of adding 100 new clinics by 2025 and 200 by 2030 [2] Company Strategy and Development Direction - The company is focusing on enhancing its research and development capabilities, particularly in natural products, while also considering the introduction of new products based on research advancements [1] - The management emphasized the importance of maintaining a balance between price increases and consumer acceptance to ensure sustainable growth [7][8] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the rising costs of raw materials, particularly natural ingredients, which have significantly impacted gross margins over the years [3][9] - The company is committed to a long-term strategy that includes careful pricing decisions and expanding its market presence through brand building and customer outreach [8] Other Important Information - The company is exploring the possibility of establishing a snake breeding operation to secure its supply of certain raw materials, although regulatory and technical challenges exist [6][8] - There is ongoing discussion about the potential for a long-term share buyback program to enhance shareholder value [9] Q&A Session Summary Question: Inquiry about R&D and product development - The management confirmed ongoing research in natural products but stated that no immediate plans for new product launches are in place [1] Question: Expansion plans for Famous Doctor Clinics - The management outlined plans to increase the number of clinics significantly, with specific targets set for the coming years [2] Question: Concerns about declining gross margins - Management acknowledged the concerns regarding gross margins and the impact of rising raw material costs, emphasizing the need for cost control and efficiency improvements [3] Question: Suggestions for dividend policy and shareholder returns - Management was receptive to suggestions regarding a stable dividend policy and acknowledged the importance of returning value to shareholders [5] Question: Concerns about inventory and supply issues - Management recognized the potential risks associated with declining inventory levels and indicated that proactive measures would be taken to avoid supply shortages [6] Question: Discussion on product shelf life and regulations - Management clarified that product shelf life is regulated and any changes would need to comply with national standards [8] Question: Proposal for a share buyback program - Management noted the sensitivity of share buyback discussions but acknowledged the importance of maintaining a stable and sustainable growth trajectory [9]

Financial Data and Key Metrics Changes - The company reported a revenue growth of 15% and a net profit growth of 13% for the year, indicating strong performance despite rising costs in raw materials [12] - The gross margin for the company is reported to be around 78-79%, which is considered high in the traditional Chinese medicine industry [12] Business Line Data and Key Metrics Changes - The company has been focusing on research and development, particularly in the area of natural products, although specific new product developments are still in the research phase [2] - The company has established over 400 medical clinics, with plans to increase this number significantly in the coming years, aiming for an additional 100 clinics by 2025 and 300 by 2035 [2] Market Data and Key Metrics Changes - The sales volume of liver disease medication increased from 3.38 million boxes at the end of 2022 to 4.53 million boxes at the end of 2023, indicating strong market demand [8] - The inventory of liver disease medication decreased from 850,000 boxes to 330,000 boxes, raising concerns about potential supply shortages [8] Company Strategy and Development Direction - The company is committed to enhancing its research capabilities and exploring new product lines, particularly in the area of natural ingredients [2] - The management is focused on maintaining a balance between price increases and consumer acceptance, ensuring that product value is reflected in pricing strategies [10] Management Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by rising raw material costs, particularly the significant increase in the price of natural ingredients like cow bile [4] - The management emphasized the importance of maintaining a sustainable growth trajectory while addressing shareholder concerns regarding profitability and pricing strategies [12] Other Important Information - The company is exploring the possibility of establishing a long-term share buyback program, potentially allocating 5-10% of annual profits for this purpose [12] - There are ongoing discussions about the potential for snake farming as a sustainable source of raw materials, although regulatory challenges exist [11] Q&A Session Summary Question: Inquiry about R&D and product development - The management confirmed ongoing research in natural products but stated that no new product launches are imminent [2] Question: Expansion plans for medical clinics - The management outlined plans to increase the number of medical clinics significantly over the next few years, with specific targets set for 2025, 2030, and 2035 [2] Question: Concerns about declining gross margin - A shareholder expressed concerns about the decline in gross margin from 85% to 75% over the past decade, attributing it to rising raw material costs [3][4] Question: Pricing strategy and inventory concerns - A shareholder raised concerns about the sustainability of sales growth given the significant reduction in inventory levels, suggesting a need for preventive pricing strategies [8] Question: Snake farming and regulatory issues - The management acknowledged the potential for snake farming but noted existing regulatory challenges that need to be addressed [11] Question: Share buyback proposal - A shareholder proposed establishing a long-term share buyback program, which the management acknowledged as a sensitive topic but indicated ongoing consideration [12]

证券代码：600436 证券简称：片仔癀 公告编号：2024-027 一、审议通过《公司关于调整董事会专门委员会的议案》； 出席会议的董事委员 9 票同意，0 票反对，0 票弃权。 为保证公司董事会下属专门委员会正常运行，根据董事会成员 变化，经全体董事的三分之一提名，董事会对提名委员会、薪酬与 考核委员会、战略委员会的委员进行调整。 原第七届提名委员会、薪酬与考核委员会、战略委员会的组成 情况如下： 提名委员会：陈蕾（主任委员）、林志辉、杜守颖、范志鹏； 薪酬与考核委员会：范志鹏（主任委员）、陈蕾、张磊； 1 / 2 漳州片仔癀药业股份有限公司 第七届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）第七届董事 会第二十次会议于 2024 年 5 月 20 日（星期一）下午 16:00 在漳州佰 翔圆山酒店三楼会议室（月季厅），以现场结合通讯方式召开。会议 通知和议案以专人送达、电子邮件方式发出。本次会议应参加表决董 事 9 人，实际表决的董事 9 人。 ...

泰和泰（北京）律师事务所 泰和泰（北京）律师事务所关于漳州片仔演药业股份有限公司 2023 年年度股东大会法律意见书 关于漳州片仔擴药业股份有限公司 2023 年年度股东大会 法律意见书 泰和泰证字[2024]PZH-02 号 泰和泰（北京）律师事务所 泰和泰(北京)律师事务所 北京市朝阳区东四环中路 56 号远洋国际中心 A 座 12 层 电话: （010）85865151 传真: （010）85861922 关于漳州片仔擴药业股份有限公司 邮政编码:100025 本所律师按照律师行业公认的业务标准、道德规范及勤勉尽责精神，对公司 提供的文件和有关事实进行了核查和验证,现出具法律意见书如下: 一、本次股东大会的召集、召开程序 泰和泰（北京）律师事务所（以下简称"本所"）接受漳州片仔廣药业股份 有限公司 ( 以下简称 " 公司" ) 的委托,指派许军利律师、殷庆莉律师对公司 2023 年年度股东大会（以下简称"本次股东大会"）进行见证,并依据《中华人民共 和国公司法》（以下简称"《公司法》"）《上市公司股东大会规则》（以下简 称"《股东大会规则》"）《上海证券交易所上市公司自律监管指引第１号―― 规范运作（2 ...

重要内容提示： 本次会议是否有否决议案：无 证券代码：600436 证券简称：片仔癀 公告编号：2024-026 漳州片仔癀药业股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1 (一) 股东大会召开的时间：2024 年 5 月 20 日 (二) 股东大会召开的地点：漳州市芗城区大桥路 1 号漳州佰翔圆山 酒店三楼（中国卉厅） (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有 股份情况： 权股份总数的比例（%） (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主 持情况等。 表决方式符合《公司法》及《漳州片仔癀药业股份有限公司章程》 （以下简称"《公司章程》"）的规定，公司董事长林志辉先生主持本 次会议。本次股东大会采用网络投票和现场投票相结合的方式进行表 决。会议的召开和表决程序符合《公司法》及《公司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席情况 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 591 | | --- | ...

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [2][14] Core Views - The report highlights that the company's core product price increases have been completed, which is expected to enhance profitability. The company reported a revenue of 10.058 billion yuan in 2023, a year-on-year increase of 15.69%, and a net profit attributable to the parent company of 2.797 billion yuan, up 13.15% [6][8]. - For Q1 2024, the company achieved a revenue of 3.171 billion yuan, reflecting a growth of 20.58%, and a net profit of 975 million yuan, which is an increase of 26.61% [6][8]. Summary by Sections Financial Performance - In 2023, the company's revenue from liver disease medications reached 4.463 billion yuan, up 24.26%, with a gross margin of 78.79%, a decrease of 2.11 percentage points year-on-year. The company raised the price of its core product, Pian Zai Huang, in May 2023, which is expected to improve gross margins in the second half of 2023 [7][8]. - The cardiovascular medication segment reported a revenue of 266 million yuan, a significant increase of 60.57%, but with a gross margin decrease of 8.44 percentage points to 38.71% [7]. Strategic Initiatives - The company is focusing on enhancing its core product, strengthening major varieties, and expanding its cosmetics line. In 2023, sales of three major products exceeded 100 million yuan each, and the cosmetics segment also achieved over 100 million yuan in sales for its flagship product [7][8]. - The company is actively pursuing innovation, with 11 clinical research projects initiated for secondary development of major products and 3 new chemical drugs entering clinical research stages in 2023 [7][8]. Profit Forecast - The company forecasts net profits attributable to the parent company for 2024, 2025, and 2026 to be 3.308 billion yuan, 3.589 billion yuan, and 4.046 billion yuan, representing year-on-year growth rates of 18.3%, 8.5%, and 12.7% respectively. The core product, Pian Zai Huang, is expected to maintain strong demand, and the company is assigned a price-to-earnings ratio of 35-45 times for 2024, corresponding to a reasonable value range of 191.93 to 246.76 yuan [6][8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 10.058 billion yuan in 2023, representing a year-on-year increase of 15.69%. The net profit attributable to shareholders was 2.797 billion yuan, up 13.15% year-on-year [4][5] - In Q1 2024, the company reported a revenue of 3.171 billion yuan, a year-on-year increase of 20.58%, and a net profit of 975 million yuan, up 26.61% year-on-year [4][5] - The company is expected to see revenue growth of 14.2%, 13.0%, and 13.8% for the years 2024, 2025, and 2026, respectively, with net profits growing by 20.8% for 2024 [9] Financial Performance Summary - In 2023, the company's overall gross margin was 46.76%, an increase of 1.12 percentage points year-on-year. The expense ratio was 13.66%, up 2.37 percentage points [5] - The pharmaceutical manufacturing segment generated revenue of 4.802 billion yuan, with a year-on-year growth of 25.94% and a gross margin of 75.77% [6] - The liver disease medication segment had revenue of 4.463 billion yuan, growing 24.26% year-on-year, with a gross margin of 78.79% [6] - The cosmetics segment reported revenue of 707 million yuan, with a year-on-year growth of 11.42% and a gross margin of 62.18% [6] Product Development and Market Strategy - The company is focusing on enhancing its flagship products and expanding its cosmetics line, with significant sales from products like An Gong Niu Huang Wan and Pi Zai Huang tablets [7] - The company is actively conducting clinical research for 11 projects related to its major products, with 3 clinical studies completed [7] - The liver disease treatment segment saw a significant revenue increase of 27.84% in Q1 2024, reaching 1.505 billion yuan, attributed to price increases [8]

漳州片仔癢药业股份有限公司 独立董事候选人声明与承诺 本人 田正大,已充分了解并同意由提名人 漳州片仔廣药业股份 有限公司董事会 提名为 漳州片仔擴药业股份有限公司第七届董事 会独立董事候选人。本人公开声明,本人具备独立董事任职资格,保 证不存在任何影响本人担任漳州片仔癢药业股份有限公司独立董事 独立性的关系,具体声明并承诺如下: 一、本人具备上市公司运作的基本知识,熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有 5 年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。 本人已经参加培训并取得深圳证券交易所颁发的《第 128 期上市 公司独立董事资格培训证书》。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求: (一)《中华人民共和国公司法》关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的规定; (三)中国证监会《上市公司独立董事管理办法》、上海证券交 易所自律监管规则以及公司章程有关独立董事任职资格和条件的相 关规定; (四)中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公 ...

漳州片仔癀药业股份有限公司 独立董事提名人声明与承诺 提名人漳州片仔癀药业股份有限公司董事会，现提名田正大先生 为漳州片仔癀药业股份有限公司第七届董事会独立董事候选人，并 已充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况。被提名人已同意出任漳州片仔癀 药业股份有限公司第七届董事会独立董事候选人（参见该独立董事 候选人声明）。提名人认为，被提名人具备独立董事任职资格，与漳 州片仔癀药业股份有限公司之间不存在任何影响其独立性的关系，具 体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、规章及其他规范性文件，具有 5 年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得深圳证券交易所颁发的《上市公司 独立董事资格培训证书》。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要 求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定； （三）中国证监会《上市公司独立董事管理办法》、上海证券交 易所自律监管规则以及公司 ...